Trial Profile
A Multicenter Randomized Comparative Study of Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine Combinations as First Line Treatment of Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Feb 2010
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Epirubicin
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Jan 2010 Results published in Annals of Oncology.
- 01 Jan 2010 Primary endpoint 'Time to disease progression' has not been met.
- 05 Mar 2007 New trial record.